M K Sannigrahi1, Rajni Sharma2, Varinder Singh1, Naresh K Panda1, Vidya Rattan3, Madhu Khullar4. 1. Department of Otolaryngology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. 2. Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. rajni.sharma28@gmail.com. 3. Unit of Oral Health Sciences, PGIMER, Chandigarh, India. 4. Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. madhu.khullar@gmail.com.
Abstract
INTRODUCTION: Epigenetic modifications have been reported to play an important role in regulating gene expression and these modifications become critical when they have a role in controlling another important layer of epigenetic regulation namely microRNAs. In the present study, we have identified the microRNAs that may be regulated by promoter DNA methylation and histone acetylation in Human papilloma virus-positive head and neck squamous cell carcinoma. METHODOLOGY: HPV-negative cell line (UPCI:SCC-116) and HPV-16 +ve cell line (UPCI:SCC-090) were treated with methylation inhibitor (5-aza-2'-deoxycytidine, AZA) and acetylation inhibitor (Trichostatin-A, TSA), followed by micro-array analysis. The differentially expressed miRNAs were validated in control (n = 10), HPV-16 +ve (n = 30), and HPV -ve (n = 30) HNC, TCGA (n = 529) tissue samples, and two HPV -ve (SCC116 and Hacat) and two HPV +ve (SCC090 and SiHa) cell lines. Methylation-specific PCR (MSP) and chromatin immunoprecipitation assay (CHIP) were performed to validate their regulation. In silico and in vitro analyses of identified miRNAs were done to study putative pathways they target and their possible role in carcinogenesis. RESULTS: Among 10 miRNAs specifically up-regulated in microarray analysis of AZA-treated SCC090 cells, we observed significantly decreased expression of hsa-miR-181c-5p, hsa-miR-132-5p, hsa-miR-658 in HPV +ve HNC cohort, TCGA tissue samples, and cell lines as compared to their HPV -ve counterpart, and their promoter region also possesses CpG islands. MSP and analysis of TCGA data (MethHC) revealed increased frequency of methylation at the promoter of hsa-miR-132-5p that is negatively correlated with its expression. In TSA-treated SCC090 cells, out of 7 miRNAs, two namely Hsa-miR-129-2-3p and Hsa-miR-449a were found to be up-regulated as compared to HPV -ve cells. However, the levels of enrichment by anti-acetyl-H3 and anti-acetyl-H4 were significantly low in cell lines compared to respective controls and both were up-regulated in HPV +ve compared to HPV -ve TCGA tissue samples. In silico analysis revealed hsa-miR-132-5p targeted canonical β-catenin/wnt pathway and modulation of down-stream genes of the pathway was observed on over-expression/inhibition of hsa-miR-132-5p. CONCLUSION: This study suggests the role of epigenetic modifications in regulating expression of miRNAs in HPV +ve HNSCC.
INTRODUCTION: Epigenetic modifications have been reported to play an important role in regulating gene expression and these modifications become critical when they have a role in controlling another important layer of epigenetic regulation namely microRNAs. In the present study, we have identified the microRNAs that may be regulated by promoter DNA methylation and histone acetylation in Human papilloma virus-positive head and neck squamous cell carcinoma. METHODOLOGY: HPV-negative cell line (UPCI:SCC-116) and HPV-16 +ve cell line (UPCI:SCC-090) were treated with methylation inhibitor (5-aza-2'-deoxycytidine, AZA) and acetylation inhibitor (Trichostatin-A, TSA), followed by micro-array analysis. The differentially expressed miRNAs were validated in control (n = 10), HPV-16 +ve (n = 30), and HPV -ve (n = 30) HNC, TCGA (n = 529) tissue samples, and two HPV -ve (SCC116 and Hacat) and two HPV +ve (SCC090 and SiHa) cell lines. Methylation-specific PCR (MSP) and chromatin immunoprecipitation assay (CHIP) were performed to validate their regulation. In silico and in vitro analyses of identified miRNAs were done to study putative pathways they target and their possible role in carcinogenesis. RESULTS: Among 10 miRNAs specifically up-regulated in microarray analysis of AZA-treated SCC090 cells, we observed significantly decreased expression of hsa-miR-181c-5p, hsa-miR-132-5p, hsa-miR-658 in HPV +ve HNC cohort, TCGA tissue samples, and cell lines as compared to their HPV -ve counterpart, and their promoter region also possesses CpG islands. MSP and analysis of TCGA data (MethHC) revealed increased frequency of methylation at the promoter of hsa-miR-132-5p that is negatively correlated with its expression. In TSA-treated SCC090 cells, out of 7 miRNAs, two namely Hsa-miR-129-2-3p and Hsa-miR-449a were found to be up-regulated as compared to HPV -ve cells. However, the levels of enrichment by anti-acetyl-H3 and anti-acetyl-H4 were significantly low in cell lines compared to respective controls and both were up-regulated in HPV +ve compared to HPV -ve TCGA tissue samples. In silico analysis revealed hsa-miR-132-5p targeted canonical β-catenin/wnt pathway and modulation of down-stream genes of the pathway was observed on over-expression/inhibition of hsa-miR-132-5p. CONCLUSION: This study suggests the role of epigenetic modifications in regulating expression of miRNAs in HPV +ve HNSCC.
Entities:
Keywords:
DNA methylation; Epigenetics; HPV-16; Head and neck cancer; MicroRNAs
Authors: M K Sannigrahi; Rajni Sharma; Varinder Singh; Naresh K Panda; Vidya Rattan; Madhu Khullar Journal: Clin Cancer Res Date: 2017-01-31 Impact factor: 12.531
Authors: Simon Papillon-Cavanagh; Chao Lu; Tenzin Gayden; Leonie G Mikael; Denise Bechet; Christina Karamboulas; Laurie Ailles; Jason Karamchandani; Dylan M Marchione; Benjamin A Garcia; Ilan Weinreb; David Goldstein; Peter W Lewis; Octavia Maria Dancu; Sandeep Dhaliwal; William Stecho; Christopher J Howlett; Joe S Mymryk; John W Barrett; Anthony C Nichols; C David Allis; Jacek Majewski; Nada Jabado Journal: Nat Genet Date: 2017-01-09 Impact factor: 38.330
Authors: Saskia M Wilting; Wina Verlaat; Annelieke Jaspers; Nour A Makazaji; Reuven Agami; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen Journal: Epigenetics Date: 2013-01-16 Impact factor: 4.528
Authors: Steven S Chang; Wei Wen Jiang; Ian Smith; Luana M Poeta; Shahnaz Begum; Chad Glazer; Shannon Shan; William Westra; David Sidransky; Joseph A Califano Journal: Int J Cancer Date: 2008-12-15 Impact factor: 7.396
Authors: C B Lajer; F C Nielsen; L Friis-Hansen; B Norrild; R Borup; E Garnæs; M Rossing; L Specht; M H Therkildsen; B Nauntofte; S Dabelsteen; C von Buchwald Journal: Br J Cancer Date: 2011-02-15 Impact factor: 7.640
Authors: Cintia M Chamorro Petronacci; Abel García García; Elena Padín Iruegas; Berta Rivas Mundiña; Alejandro I Lorenzo Pouso; Mario Pérez Sayáns Journal: Medicina (Kaunas) Date: 2020-10-13 Impact factor: 2.430